Butylscopolamine

Summary

Butylscopolamine (CHEMBL1618102) is an approved small-molecule muscarinic antagonist (ATC A03BB01); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03BB01
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 360.5 Da · C21H30NO4+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1618102
Name	Butylscopolamine
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	160883
ChEBI	CHEBI:145701
ATC	A03BB01
Molecular formula	C21H30NO4+
Molecular weight	360.5
InChIKey	YBCNXCRZPWQOBR-MWGADRMYSA-N

SMILES: CCCC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C

IUPAC name: [(1R,2R,4S,5S)-9-butyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate

ChEBI definition: A carboxylic ester resulting from the formal condensation of the carboxy group of (2S)-3-hydroxy-2-phenylpropanoic acid with the hydroxy group of (2R,4S,5S,7s)-9-butyl-7-hydroxy-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane.

Pharmacological roles (ChEBI): muscarinic antagonist, antispasmodic drug.

Also known as: Butylscopolamine, N-butylscopolammonium, N-butylscopolammonium cation, N-butylscopolammonium ion, BUTYLSCOPOLAMINE, BUTYLSCOPOLAMINE BROMIDE, scopolamine butylbromide

Parent form; salt/anhydrous children: CHEMBL1256901

Patent coverage: 5 distinct patent families (6 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM2	6.44	AC50	365.5	nM	CHEMBL_ACT_25195802
KCNH2	5.55	AC50	2800	nM	CHEMBL_ACT_25117749
CHRM1	5.33	AC50	4724	nM	CHEMBL_ACT_25210270

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03961165	PHASE3	COMPLETED	BUSCLAB - Buscopan to Prevent Slow Progress in Labor

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).